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Citrus grandis (L.) Osbeck (red wendun) leaves have been used in traditional Chinese medicine to treat several illnesses including
diabetes. However, there is no scientiﬁc evidence supporting these actions and its active compounds. Two ﬂavone glycosides,
rhoifolin and cosmosiin were isolated for the ﬁrst time from red wendun leaves and, identiﬁed these leaves are rich source
for rhoifolin (1.1%, w/w). In diﬀerentiated 3T3-L1 adipocytes, rhoifolin and cosmosiin showed dose-dependent response in
concentration range of 0.001–5μM and 1–20μM, respectively, in biological studies beneﬁcial to diabetes. Particularly, rhoifolin
and cosmosiin at 0.5 and 20μM, respectively showed nearly similar response to that 10nM of insulin, on adiponectin secretion
level. Furthermore, 5μM of rhoifolin and 20μM of cosmosiin showed equal potential with 10nM of insulin to increase the
phosphorylation of insulin receptor-β, in addition to their positive eﬀect on GLUT4 translocation. These ﬁndings indicate that
rhoifolin and cosmosiin from red wendun leaves may be beneﬁcial for diabetic complications through their enhanced adiponectin
secretion, tyrosine phosphorylation of insulin receptor-β and GLUT4 translocation.
1.Introduction
The worldwide prevalence of type 2 diabetes is increasing
at a staggering rate. It has been estimated that by the
end of this decade, the number of people having type 2
diabetes will grow to in excess of 320 million [1]. Type 2
diabetes is characterized by an insensitivity of peripheral
tissues to the action of insulin, termed insulin resistance.
Binding of insulin to its speciﬁc cell surface receptor induces
receptor autophosphorylation that triggers the activation of
two main intracellular signaling pathways: the phosphatidyl-
inositol-3-kinase (PI3K) pathway involved in glucose trans-
port and glycogen synthesis, and the extracellular regulated
kinase (ERK) pathway involved in gene expression and
cell proliferation mechanisms. Resistance to insulin can
appear at various levels of these signaling pathways [2].
On the other hand, adiponectin is an important endocrine
secreted cytokine which aﬀect insulin sensitivity through
modulation of insulin signaling pathway [3]. The functions
of adiponectin have been the focus of recent attention
because accumulating evidence has shown that there are
close relationships between circulating adiponectin levels
and a variety of lifestyle-related diseases, including obesity,
coronary artery disease, type 2 diabetes and metabolic
syndrome,andadiponectinexhibitsinsulin-sensitizing,anti-
diabetic and anti-atherogenic activities [4]. Collectively, it
is reasonable to consider that adiponectin represents a
useful target for treating or preventing insulin resistance,
type 2 diabetes. Current pharmacological approach using
thiazolidinediones (TZD) such as pioglitazone (PGZ) and
rosiglitazone in the treatment of type 2 diabetes have
undesirable side eﬀects including weight gain [5], ﬂuid
retention, the worsening of coronary heart disease [6], and
an increased risk of myocardial infarctions [7]. With these
points in mind, the search for alternative therapy to combat
type 2 diabetes is warranted.2 Evidence-Based Complementary and Alternative Medicine
In recent years, much attention has been paid to the dis-
covery of natural products that may be beneﬁcial in reducing
the risks of diabetes, because these are usually considered to
be less toxic, with fewer side eﬀects than synthetic drugs [8–
14]. In this connection, with the distinctive medical opinions
thetraditionalChineseherbsandherbalformulaeperformed
a good clinical practice and showing a bright future in
the therapy of diabetes mellitus and its complications [15].
Citrus grandis (L.) Osbeck of the family Rutaceae is widely
cultivated in subtropical areas of Asia. Red wendun is the
l o c a ln a m ef o rC. grandis Osbeck in the Taiwan. The essential
oil of this species is used as the major ingredients of ﬂavor,
the leaves are used as a food ﬂavoring, and dried leaves are
brewed in water as a drink [16]. Red wendun leaves have long
beenusedasherbalremediesintraditionalChinesemedicine
to promote blood circulation and remove blood stasis in
diseases caused by blood stagnation [17]. For these reasons,
red wendun is a traditional Chinese anti-diabetic medicine.
However, there is no report on the identities and their mech-
anisms underlying the anti-diabetic action of constituents
from red wendun leaves. Therefore, in the present study we
used diﬀerentiated 3T3-L1 adipocytes to identify potential
agentswhichenhancedadiponectinsecretion,tyrosinephos-
phorylation of the insulin receptor (IR)-β subunit, as well
as glucose transporter4 (GLUT4) translocation with insulin-
mimetic activity. Our ﬁnding will signiﬁcantly contribute to
the growing knowledge about red wendun leaves for their
application in the treatment of diabetic disease.
2. Methods
2.1. General. All the materials were obtained commercially
and used without further puriﬁcation. NMR spectra were
measuredonVarianUnityInova-600VXR-300/51spectrom-
eter, using TMS as an internal standard. Silica gel for column
chromatography (CC), (0.063–0.200mm), was a product of
Merck Company. TLC was performed on Merck TLC plates
(0.23mmthickness),withcompoundsvisualizedbyspraying
with8%(v/v)H2SO4 inethanol(EtOH)andthenheatingon
ah o tp l a t e .
Dexamethasone (DEX), 3-isobutyl-1-methylxanthine
(IBMX), insulin (I) and phenylmethylsulfonylﬂuoride
(PMSF) were purchased from Sigma Aldrich Chemical (St.
Louis, MO, USA). Dulbecco’s Modiﬁed Eagle’s Medium
(DMEM), fetal bovine serum (FBS), and antibiotic mix-ture
(penicillin-streptomycin) were purchased from the Invitro-
gen Co. (Carlsbad, CA, USA). Polyvinyldiﬂuoride (PVDF)
membrane for western blotting was obtained from Millipore
(Bedford, MA, USA). Primary antibodies anti-GLUT4,
anti-insulin receptor β and anti-adiponectin were obtained
from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
The antibody anti-rabbit IgG conjugated with horseradish
peroxidase (HRP) were purchased from the Amersham-
Pharmacia Biotech (Arlington Heights, IL, USA). All other
chemicals were reagent grade or higher and obtained from
commercial sources.
2.2. Plant Material, Extraction, and Isolation. Citrus grandis
(L.) Osbeck leaves were collected from the Madau, Tainan
County, Taiwan, in October 2008. The species was identiﬁed
by one of the author Dr. Yew-Min Tzeng at Natural Products
& Bioprocess Laboratory, Chaoyang University of Technol-
ogy. A voucher specimen (YMT 8001) was deposited in
the Herbarium of the Institute of Biochemical Sciences and
Technology, Chaoyang University of Technology, Taiwan,
ROC.
The air-dried leaves (600g) of C. grandis were extracted
with methanol (61×4) under reﬂux. After exhaustive
extraction, the combined extracts were concentrated under
reduced pressure to give dark brown syrup of ∼37g (6.1%
based on the dry weight of leaves). The crude extract was
then suspended in H2O, defatted with n-hexane, and then
partitioned with chloroform and n-butanol successively. The
concentrated n-butanol layer (15g) was subjected to silica
gel CC and eluted with increasing polarity using mixtures
of CHCl3/MeOH. Following the TLC analysis, eluates of
similar proﬁles were combined to give ﬁve fractions (F1–
F5). Fraction F2 (1.2g) was rechromatographed over a silica
gel column using CHCl3/MeOH (95:5 and 90:10) to aﬀord
compound 2 as a yellow solid, identiﬁed as cosmosiin or
apigenin-7-O-β-glucoside (125mg, 0.021%). Fraction F3
(9.3g) was puriﬁed further by chromatography on silica
g e lw i t hC H C l 3/MeOH, resulting in compound 1 as yellow
amorphous powder, identiﬁed as rhoifolin or apigenin-7-O-
β-neohesperidoside (6.7g, 1.1%). The structures of rhoifolin
and cosmosiin (Figure 1) were established by comparison of
theirNMRspectraldatawiththosereportedintheliterature.
2.2.1. Rhoifolin. Yellow amorphous powder; UV (MeOH)
λmax (logε): 268 (4.32), 335 (4.1); 1H NMR (DMSO-d6): δ
7.95 (2H, d, J = 8.5Hz, H-2 ,6  ), 6.95 (2H, d, J = 8.5Hz,
H-3 ,5  ), 6.87 (1H, s, H-3), 6.79 (1H, d, J = 1.5Hz, H-8),
6.37 (1H, d, J = 1.5Hz, H-6), 5.23 (1H, d, J = 7.5Hz, H-
1  ), 5.13 (1H, brs, rham-1), 3.20–3.88 (sugar protons), 1.20
(1H, d, J = 6.0 Hz, rham-6); 13C NMR (DMSO-d6) δ 181.9
(C = O), 164.3 (C-2), 162.5 (C-7), 161.4 (C-4 ), 161.1 (C-
5), 156.9 (C-9), 128.6 (C-2 ,6  ), 121.0 (C-1 ), 116.0 (C-3 ,
5 ), 105.4 (C-10), 103.2 (C-3), 100.5 (C-1  ), 99.3 (C-6), 97.8
(C-1   ), 94.5 (C-8), 77.2 (C-3  ), 77.0 (C-5  ), 76.3 (C-2  ),
71.9 (C-4   ), 70.5 (C-2   ), 70.4 (C-3   ), 69.6 (C-4  ), 68.3
(C-5   ), 60.5 (C-6  ), 18.1 (C-6   ); ESI-MS (positive mode)
m/z 579.1 [M + H]
+ [18].
2.2.2. Cosmosiin. Yellow solid; UV (MeOH) λmax (log ε): 266
(4.3), 337 (3.9); 1H NMR (DMSO-d6): δ 8.02 (2H, d, J =
8.5Hz,H-2 ,6  ),6.89(2H,d,J = 8.5Hz,H-3 ,5  ),6.87(1H,
s, H-3), 6.78 (1H, s, H-8), 6.27 (1H, s, H-6), 5.01 (1H, d, J =
7.5Hz,H-1  ),3.20–3.88(sugarprotons); 13CNMR(DMSO-
d6) δ 182.1 (C = O), 163.9 (C-2), 162.6 (C-7), 161.1 (C-4 ),
160.4(C-5),156.0(C-9),128.5(C-2 ,6  ),121.6(C-1 ),115.8
(C-3 ,5  ), 104.6 (C-10), 104.0 (C-3), 102.4 (C-1  ), 98.9 (C-
6), 98.1 (C-8), 78.6 (C-3  ), 73.4 (C-5  ), 70.8 (C-2  ), 70.5
(C-4  ), 61.3 (C-6  ); ESI-MS (positive mode) m/z 433.1 [M
+H ]
+ [19].
2.3. T3-L1 Adipocyte Culture. 3T3-L1 ﬁbroblasts were pur-
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Figure 1: Chemical structures of rhoifolin (1) and cosmosiin (2)
isolated from C. grandis leaves.
(BCRC, Food Industry Research and Development Institute,
Taiwan, ROC). The cells were cultured as described earlier
[20]. Fibroblasts were grown to conﬂuence in 25mM
glucose DMEM containing 10% new calf serum and peni-
cillin/streptomycin (100IU and 100μgmL 1,r e s p . )i na
humidiﬁed atmosphere containing 5% CO2.D i ﬀerentiation
to the adipocyte phenotype was induced by incubating cells
in DMEM containing 10% FBS, 0.2nM insulin, 0.25mM
DEX, and 0.5mM IBMX for 48h. Cells were then incubated
for an additional 48h in DMEM containing 10% FBS and
0.2nM of insulin. After diﬀerentiation, adipocytes were
maintained in normal culture medium (DMEM, 25mM
glucose and 10% FBS) and was freshly replaced every
48h. Unless indicated otherwise, cells were used 9 days
after diﬀerentiation induction when exhibiting more than
90% adipocyte phenotype. Stock solutions of rhoifolin and
cosmosiin were prepared in DMSO, and equal volume of
DMSO (ﬁnal concentration <0.1%) was added to control
samples.
2.4. Cell Viability (MTT Assay). For cell viability, 3T3-L1
cells were seeded in 24-well plates at density of 4×104
cells mL1. When they reached 90% conﬂuence, the cells
were treated with diﬀerent concentrations of rhoifolin and
cosmosiin for 24h. Cell viability was determined using
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide at 0.5mgmL1 concentration. Treatments were
replicated in four wells and experiments repeated at least
three times.
2.5. Lactate Dehydrogenase Activity (LDH Assay). For cell
viability, 3T3-L1 cells were seeded in 24-well plates at density
of 4×104 cells mL1. When they reached 90% conﬂuence,
the cells were treated with diﬀerent concentrations of
rhoifolin and cosmosiin for 24h. After 24h of culture with
tested compounds treatment, LDH assay was performed
using LDH cytotoxicity detection kit (Takara, Otsu, Shiga,
Japan) according to the manufacturer’s instructions. Data
are presented as cytotoxicity (%) = (experimental value low
control)/(high control low control) × 100. High control =
maximum release of LDH at cell lysis, low control = medium
with cultured cells.
2.6. Western Blot. 3T3-L1 adipocytes were transferred to a
serum-free medium for 3h after 8 days after the initiation
of diﬀerentiation, and then incubated with 0–20μMo f
rhoifolin and cosmosiin at 37◦C in a humidiﬁed 5%CO2
incubator. The incubation period for adiponectin secretion
and tyrosine phosphorylation of IRβ were 24h and 20min,
respectively. Cells were collected and lysed in ice-cold lysis
buﬀer(1mMTris-HCl,1mMEDTA,pH8.0,200mMPMSF,
1mM aprotinin, 1% protease inhibiter cocktail). Culture
medium was concentrated by freeze drying and reconstitu-
tion. Protein extractions or concentrated culture medium
were separated by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) using a 7.5% PAGE. The
proteins in the gel were transferred to a PVDF membrane.
The PVDF membrane was blocked with 5% skimmed milk
in PBST (0.05% v/v Tween-20 in PBS, pH 7.2) for 1h.
Membranes were incubated with primary antibody at 4◦C
overnight. Primary antibodies used were: anti-adiponectin
(1:1000), anti-insulin receptor-β and anti-GLUT4 (1:200).
Speciﬁc antibody binding was detected by HRP-conjugated
secondary antibodies and visualized using western blot
detection system (ECL Plus, Amersham, UK). The band
densities were quantiﬁed using an image analyzer NIH
Image software. All protein quantiﬁcations were adjusted for
the corresponding β-actin level, which was not consistently
changed by the diﬀerent treatment conditions.
2.7. GLUT4 Translocation. For GLUT4 translocation studies
adipocytes were grown on poly-l-lysine coated cover glass
and incubated in the presence or absence of either insulin
or compounds (rhoifolin and cosmosiin) at 37◦C for 20min.
Thecellswereﬁxedwith4%paraformaldehyde,blockedwith
1% horse serum for 1h, followed by incubation with two
primary antibodies (GLUT4/Na+-K+ ATPase (Upstate)) in
PBST (0.1% Tween-20) at 4◦C overnight. After PBS wash,
the cells were treated with secondary antibodies (anti-goat
IgG conjugated with Alexa Fluor 488 and anti-rabbit IgG
conjugated with cy3). The stained cells were visualized and
photographed using an Axioscope ﬂuorescent microscope
(Zeiss, Oberkochen, Germany).
2.8.StatisticalAnalysis. Allval uesw er ee xpr essedasmeans±
SD and one-way ANOVA was used to determine signiﬁcance
of treatment eﬀects at each time point. Diﬀerences among
treatment means were determined by Tukey’s test and P-
values were considered signiﬁcant at ∗P<. 05, ∗∗P<. 01.
3. Results
3.1. Tested Compounds Rhoifolin and Cosmosiin Are Not
Cytotoxic. We ﬁrst examined the safety of rhoifolin and
cosmosiin on diﬀerentiated 3T3-L1 cells viability using the
MTT method and LDH release. As shown in Figure 2,
compared with untreated control cells, no signiﬁcant change
in viability was observed at various concentrations tested
for an incubation period of 24 h (Figure 2). LDH release
by rhoifolin and cosmosiin treatment did not increase in
diﬀerentiated 3T3-L1 cells (Figure 2). We conclude that4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Cell viability analysed by MTT and LDH release assays after 24h of addition of tested compound or insulin in diﬀerentiated 3T3-
L1 cells. Diﬀerentiation of 3T3-L1 cells was initiated after conﬂuence for 2 days with IBMX and dexmethasone, and compounds were added
9d a y sa f t e rd i ﬀerentiation for 24h.
rhoifolin and cosmosiin did not aﬀect proliferation of
diﬀerentiated 3T3-L1 cells.
3.2.ResponseofRhoifolinandCosmosiinonAdiponectinSecre-
tion. Next, to explore the acute response of rhoifolin and
cosmosiin on adiponectin secretion, diﬀerentiated 3T3-L1
adipocytes were treated with 10nM of insulin or increasing
concentrations of rhoifolin (0.01μM, 0.1μM, 0.5μM, 1μM,
and 5μM) and cosmosiin (1μM, 10μM, and 20μM) for 24h
and their action on the cells responsiveness to adiponectin
release was measured by western blot. As shown in Figure 3,
comparisons indicate that secreted adiponectin level in
treated sample was signiﬁcantly diﬀerent from those of the
control. Rhoifolin and cosmosiin showed dose-dependent
response in adiponectin secretion levels compared with that
of control (Figure 3). The stimulatory response of rhoifolin
was maximal at 0.5μM with increased adiponectin level by
1.7-fold (Figure 3(a), lane 3) and, this response was similar
to that of insulin at 10nM (Figure 3(a), lane I). It should
be noted that higher concentrations 1μM( Figure 3(a),l a n e
4) and 5μM( Figure 3(a), lane 5) of rhoifolin had similar
response with 0.5μM of the same compound (Figure 3(a),
lane 3). Thus, 0.5μM of rhoifolin was ideal for maximal
adiponectinsecretion3T3-L1adipocytes.Ontheotherhand,
cosmosiin increased adiponectin levels by 2.3 (Figure 3(b),
lane 1), 3.8 (Figure 3(b), lane 2), and 11.6 (Figure 3(b),l a n e
3)-fold at concentration of 1, 10, and 20μM, respectively,
whereas insulin (Figure 3(b), lane I) enhanced the same by
13.7-fold at 10nM.
3.3. Rhoifolin and Cosmosiin Enhance Phosphorylation of
I n s u l i nR e c e p t o r( p I R ) - β. The levels of tyrosine pIR-β in
response to 10nM insulin or diﬀerent concentrations of
rhoifolin and cosmosiin were determined by western blot
with anti-pTyr antibody (Figure 4). As shown in Figure 4,
lower concentrations of rhoifolin at 0.01μM( Figure 4(a),
lane 1), and 0.1μM( Figure 4(a), lane 2) had no signiﬁcant
response compared with control (Figure 4(a),l a n eC )o n
enhanced pIR-β level. However, rhoifolin at concentrations
of 0.5μM( Figure 4(a),l a n e3 ) ,1 μM( Figure 4(a),L a n e
4), and 5μM( Figure 4(a), lane 5) showed dose-dependent
response and, pIR-β levels enhanced by 1.1-, 1.6-, and 3.9-
fold, respectively. The response of rhoifolin at 5μMo n
enhanced pIR-β level was similar to that of insulin at 10nM
(Figure 4(a), lane I). On the other hand, cosmosiin showed
a dose-dependent response and, pIR-β levels enhanced by
0.5-, 0.6-, and 2.2-fold when the cells were treated with 1μM
(Figure 4(b),l a n e1 ) ,1 0μM( Figure 4(b), lane 2), and 20μM
(Figure 4(b),lane3),respectively.Itisobservedthatrhoifolin
potentially enhanced pIR-β level compared with cosmosiin,
in addition, 5μMo ff o r m e r ,a n d2 0 μM of latter showed
nearly similar response to that of insulin at 10nM.Evidence-Based Complementary and Alternative Medicine 5
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Figure 3: Eﬀect of rhoifolin and cosmosiin on the adiponectin secretion from 3T3-L1 adipocytes. Nine days after the initiation of
diﬀerentiation, cells were treated with control medium or test compounds for 24h at 37◦C. (a) Control medium (C); 10nM insulin (I);
rhoifolin 0.01μM (lane 1), 0.1μM (lane 2), 0.5μM( l a n e3 ) ,1μM (lane 4), and 5μM (lane 5). (b) Control medium (C); 10nM insulin (I);
cosmosiin 1μM (lane 1), 10μM (lane 2), and 20μM (lane 3). Secreted adiponectin was quantiﬁed by western blotting with antibody. The
blots shown are one representative of three independent experiments. Values are means ± S.D. of three experiments and ∗P<. 05; ∗∗P<. 01
versus control.
3.4. GLUT4 Translocation Was Enhanced by Rhoifolin and
Cosmosiin Treatment. We then examined the action of
rhoifolin and cosmosiin on the glucose transport system
in diﬀerentiated 3T3-L1 adipocytes. As shown in Figure 5,
the control cells double stained with GLUT4 and nucleus
marker DAPI, the GLUT4 immunoreactivity was localized
near the nucleus at the Golgi apparatus. However, after
stimulation with 10nM of insulin or various concentrations
of rhoifolin (0.5, 1, and 20μM) and cosmosiin (1, 10, and
20μM), GLUT4 immunoreactivity moved to the plasma
membraneandwasnotlocalizednearthenucleus(Figure 5).
At0.01μM,0.1μMofrhoifolinGLUT4translocationwasnot
signiﬁcantandGLUTimmunoreactivitywaslocatednearthe
nucleus.
4. Discussion
Although traditional herbal medicines have been practiced
for diabetic complications; however, proper mechanism
of active compounds of these medicines are not well-
understood to support their scientiﬁc merit over the existing
therapies [21]. This study may provide an initial insight into
the possible mechanism of action of red wendun leaves as
anti-diabetic. In this study, the MeOH extract of red wendun
leaves was subjected to solvent fractionation and, n-butanol
fraction was puriﬁed using a silica gel chromatography,
which led to the isolation of two ﬂavonoids rhoifolin (1)
and cosmosiin (2)( Figure 1). To our knowledge these two
ﬂavonoids were isolated for the ﬁrst time from red wendun
leaves and, identiﬁed these leaves are rich source for the
molecule rhoifolin (1.1%, w/w).
Flavonoids are a large group of polyphenolic phyto-
chemicals found in a variety of plant kingdom, medicinal
herbs, vegetables and fruits. These natural products are of
interest because of their diverse biological activities, such
as anti-atherosclerotic, anti-inﬂammatory, anti-cancer and
anti-diabetic actions [22]. Their anti-diabetic role has been
indicated in some large, prospective studies. For example,
a ﬂavonol diglycoside, kaempferol-3-neohesperidoside has a
signiﬁcant hypoglycemic eﬀect in diabetic rats and stimulate
glucose uptake in rat soleus muscle mimicking insulin
signaling [23, 24]. Also, genistein and daidzein ﬂavonoids
have been reported as insulin-secretagogues since they
increased serum insulin secretion stimulated by glucose in
vivo and in vitro [25]. Apigenin, the aglycone of rhoifolin
and cosmosiin also reported to have stimulatory eﬀect
on glucose uptake [26]. The present compounds rhoifolin
and cosmosiin previously reported to have anti-oxidant
and immunomodulatory activities [27, 28]. In this study,
no appreciable change in cell viability assays (MTT and6 Evidence-Based Complementary and Alternative Medicine
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Figure 4:Eﬀectofrhoifolinandcosmosiinonthephosphorylationlevelofinsulinreceptor-β.Ninedaysaftertheinitiationofdiﬀerentiation,
cells were treated with control medium or test compounds for 20 min at 37◦C, and then lysates were prepared. (a) Control medium (C);
10nM insulin (I); rhoifolin 0.01μM (lane 1), 0.1μM (lane 2), 0.5μM( l a n e3 ) ,1μM (lane 4), and 5μM (lane 5). (b) Control medium (C);
10nM insulin (I); cosmosiin 1μM (lane 1), 10μM (lane 2), and 20μM (Lane 3). Phosphorylation of IRβ was assessed by western blot with
anti-phospho-IRβ antibody. Values are means ± SD of three experiments and ∗P<. 05; ∗∗P<. 01 compared with control.
LDH release) of diﬀerentiated 3T3-L1 cells was observed,
suggesting that rhoifolin and cosmosiin did not aﬀect cell
growth of 3T3-L1 cells (Figure 2).
Adiponectin is one of the most abundant secretary
proteins in the adipose tissue of both rodents and humans.
Adiponectin is thought to have novel insulin-sensitizing
property in vitro and in vivo, and suggested that it plays a
protective role against insulin resistance [4]. In the present
study, we observed that an increase in adiponectin levels
in diﬀerentiated 3T3-L1 adipocytes treated with rhoifolin
and cosmosiin after 24h of incubation (Figure 3). Based on
the similarity of cellular eﬀects elicited by the compounds
rhoifolin and cosmosiin and, insulin, it is not surprising
to ﬁnd that, like insulin, isolated compounds can stimulate
adiponectin release. In relation to the present studies, it must
be noted that a polymethoxy ﬂavonoid nobiletin isolated
from Citrus depressa promoted adiponectin secretion in
a concentration-dependent manner in ST-13 cells [29]. A
biﬂavone isoginkgetin isolated from the leaf extracts of
Ginkgo biloba also reported to enhanced adiponectin pro-
duction in 3T3-L1 adipocytes [30]. Furthermore, it has been
reported that anti-diabetic drug pioglitazone shown to have
insulin-like activities through increase adiponectin secretion
in 3T3-L1 adipocytes [31]. It is thus possible that rhoifolin
a n dc o s m o s i i nc o u l dh a v ei nl a n ee ﬀect of these known anti-
diabetic compounds in terms of adiponectin secretion. Our
study ﬁrst provides evidence that rhoifolin and cosmosiin
elevates the production of adiponectin secretion in 3T3-
L1 adipocytes. Future studies will be required to determine
the mechanisms by which rhoifolin and cosmosiin increases
adiponectin secretion and/or expression.
The action of insulin is initiated by its binding to the
insulin receptor (IR). This leads to autophosphorylation
of the insulin receptor (pIR) and this, in turn, leads to
activation of number of proteins including insulin receptor
substrate (IRS) and phosphatidylinositol 3-kinase (PI3K, see
Figure 6). Recently, small-molecule compounds have been
discovered that speciﬁcally bind to the IR and augment IR-
dependent signal transduction cascade, thereby mimicking
the action of insulin and could be useful in the treatment
of type 2 diabetes [32]. Our results showed that 5μM
of rhoifolin and 20μM of cosmosiin have nearly similar
response to that of insulin at 10nM on pIRβ (Figure 4).
These ﬁndings suggested that the stimulation of adiponectinEvidence-Based Complementary and Alternative Medicine 7
5 μM
1 μM
0.5 μM
0.1 μM
0.01 μM
20 μM
10 μM
1 μM
Control
Insulin (10nM)
Cosmosiin Rhoifolin
Figure 5: Rhoifolin and cosmosiin stimulated GLUT4 translocation in the 3T3-L1 adipocytes. Cells were starved for 3h in serum-free
medium, then insulin, or diﬀerent concentrations of rhoifolin and cosmosiin added for 30min. The subsequent GLUT4 translocation was
visualized by ﬂuorescent immunostaining. GLUT4 (red) immunoreactivity was observed near the nucleus (blue) or distributed evenly on
the plasma membrane.
secretion by these ﬂavones is partly related to the enhanced
pIR-β and, adipocytes could be target sites to exert their
insulin-mimetic activity.
GLUT4 plays an important role in stimulating glucose
uptake into muscles and adipocytes. This is achieved by
increasing the membrane translocation and activation of
GLUT4 in an insulin-dependent or independent manner
[33]. Compounds that potentiate GLUT4 translocation to
the membrane can be beneﬁcial for the treatment of
metabolic syndrome and type 2 diabetes [33]. Extracts from
diﬀerent plants were reported to modulate glucose uptake
activityinculturedcells.However,veryfewstudieshavebeen
carried out to isolate and characterize the active compound/s
fromthecrudeextractsandunderstandthemolecularmech-
anism by which these compounds aﬀect glucose uptake [34–
36]. Our observations revealed activated GLUT-4 transloca-
tion to the membrane by insulin in diﬀerentiated 3T3-L1
adipocytes(Figure 5).Inaddition,itisalsoidentiﬁedthatthe
varying concentrations of rhoifolin and cosmosiin isolated
from red wendun leaves facilitated the GLUT4 transloca-
tion (Figure 5). The GLUT4 translocation pattern by these
ﬂavone glycosides is similar to that of pIRβ, suggesting that
the GLUT4 translocation by these compounds is involved
in stimulation of insulin signaling by enhanced pIR-β8 Evidence-Based Complementary and Alternative Medicine
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Figure 6: Insulin signaling pathway in adipocytes: showing poten-
tial sites of rhoifolin and cosmosiin interactions.
(Figure 6). Although the detailed mechanisms of action need
to be investigated further, this is the ﬁrst study to reveal the
potential insulin-mimetic eﬀects of rhoifolin and cosmosiin
based on their enhanced adiponectin secretion, pIR-β and
GLUT4 translocation (Figure 6). Thus, the present results
provide a possible explanation for the anti-diabetic eﬀects
of red wendun leaves. The results of this study showed that
rhoifolin was potent than cosmosiin in terms of adiponectin
secretion, pIR-β and GLUT4 translocation, which might be
attributable to the presence of additional rhamnose moiety
in rhoifolin.
In conclusion, this study presents for the ﬁrst time that
compounds rhoifolin and cosmosiin from red wendun leaves
might exert their anti-diabetic eﬀects through enhanced
adiponectin secretion, phosphorylation of insulin receptor-
β, and GLUT4 translocation. The leaves of red wendun are
a rich source for the molecule rhoifolin (1.1%, w/w). The
present compounds may be useful to develop potent lead
compoundsforthetreatmentofdiabetesthroughpromoting
the adiponectin secretion and tyrosine phosphorylation of
insulin receptor-β and GLUT4 translocation. The critical
genes involved in rhoifolin and cosmosiin action may
provide novel targets to combat insulin resistance associated
diseases.
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